Alamar Biosciences, Inc. (ALMR) · Aug 10, 2026 · Earnings

Revenue surged, but heavier spending keeps the read firmly mixed

Revenue surged, but heavier spending keeps the read firmly mixed

There is no clean published Q2 revenue benchmark to call a beat or miss. Available public estimate pages identify analyst coverage but do not provide a usable Q2 revenue consensus in the accessible results, while the company had not issued full-year 2026 guidance as of its May 8 report. The appropriate anchor is therefore the prior quarter's $26.0 million revenue and the market's broad expectation for continued rapid post-IPO growth—not the company's promotional wording.

The top line continued to outperform its own recent pace. Q2 revenue reached $29.4 million, up 82% year over year and roughly 13% above Q1's $26.0 million. Consumables were the clear engine at $15.5 million, up 147%, while instruments grew 35% to $7.8 million and services rose 49% to $6.2 million (Revenue by source). That mix matters because consumables carry better economics and support a recurring pull-through model.

MetricQ2 2026Q2 2025Change / context
Total revenue$29.4M$16.2M+82% (Income Statement)
Instruments$7.8M$5.8M+35% (Revenue by source)
Consumables$15.5M$6.3M+147% (Revenue by source)
Services$6.2M$4.1M+49% (Revenue by source)
Gross margin60%53%+7 percentage points (Financial Results)
Operating expenses$31.3M$16.5M+89% (Income Statement)
Operating loss$(13.5)M$(7.9)MLoss widened (Income Statement)
Net loss$(13.2)M$(7.0)MLoss widened (Income Statement)
Cash, investments and restricted cash$256.3M—As of June 30, 2026 (Balance Sheets / Financial Results)

The profitability improvement is real at the gross-profit level, but not yet reaching the bottom line. Gross margin expanded to 60% from 53% as consumables became a larger share of sales and manufacturing efficiency improved (Financial Results). However, operating expenses rose 89%, faster than revenue, driven by hiring, infrastructure, R&D and public-company costs; operating loss consequently widened to $13.5 million (Income Statement). Stock-based compensation also increased to $3.3 million from $0.7 million (Stock-based compensation table), so the quarter shows operating leverage potential rather than delivered operating leverage.

The new guidance is constructive but not a clear upside reset. Full-year revenue guidance of $116 million to $120 million implies a $118 million midpoint and 59% growth over 2025 (2026 Guidance). With $55.5 million recorded in the first half (Income Statement), the company needs $60.5 million to $64.5 million in the second half—roughly $30.3 million to $32.3 million per quarter—to reach the range. That requires continued sequential growth, but the filing does not say the range was raised from an earlier forecast; it is the first formal full-year guide, so its signal is more about establishing a credible growth path than delivering a measurable guidance beat.

Net read: strong demand, better mix, but still an investment story rather than an earnings story. The revenue trajectory and consumables acceleration are better than a merely steady-growth outcome, and the $256.3 million liquidity position materially supports continued investment (Balance Sheets). But without a substantiated consensus comparison—and with operating losses widening—the filing earns a mixed read: commercially strong, financially still dependent on future scale to convert growth into earnings.

Original filing on SEC EDGAR

More Alamar Biosciences, Inc. news

Revenue surged, but heavier spending keeps the read firmly mixed | ALMR Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.